The Broken Promise Doctrine: AstraZeneca Canada Inc v Apotex Inc and the Future of Pharmaceutical Patents

In AstraZeneca Canada Inc v Apotex Inc, the Supreme Court of Canada abolished the so-called promise doctrine in patent law. Large pharmaceutical companies that sought greater patent protections through litigation routinely mischaracterized the promise doctrine. To demonstrate that mischaracterizatio...

Full description

Saved in:
Bibliographic Details
Published in:Appeal, review of current law and law reform review of current law and law reform, 2022-01 (27), p.70
Main Author: Wagner, Darren N
Format: Article
Language:English
Subjects:
Litigation
Patent law
Pharmaceutical industry
Supreme Court decisions
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 27
container_start_page 70
container_title Appeal, review of current law and law reform
container_volume
creator Wagner, Darren N
description In AstraZeneca Canada Inc v Apotex Inc, the Supreme Court of Canada abolished the so-called promise doctrine in patent law. Large pharmaceutical companies that sought greater patent protections through litigation routinely mischaracterized the promise doctrine. To demonstrate that mischaracterization, this case comment begins by examining historical and international perspectives that informed the Supreme Court's decision. This paper then turns to a critical yet subjective element of the decision: the analysis of the meaning and purpose of "use" and "useful" in the Patent Act. The reasons for the decision are then considered against the advantages that more stringent utility requirements offer to both patent law and the pharmaceutical industry. This paper concludes with the recent legacy of the decision and recommendations for why and how the courts might seek a middle ground for utility promises in patents.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2666962116</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2666962116</sourcerecordid><originalsourceid>FETCH-LOGICAL-p113t-6ef0ee5f2f8cdc1810116d5839c1c2de9f0f2aee4f34fc7e5a066f0697dee56a3</originalsourceid><addsrcrecordid>eNotzc1KAzEUBeAsFKzVd7jgeiA_nXTG3ThaLRScRQVxUy7JDZ3aJmOSER_fwbo6nMX5zgWbCcnLQgv5fsWuUzpwLiuu5Iz12z3BQwyf5KGL4dQngsdgcuw93UOTcsQP8mQQWvRoEdbewDc0Q8j081fQW8gTshrzGAmCg26P8YSGxtwbPEKHmXxON-zS4THR7X_O2dvqadu-FJvX53XbbIpBCJULTY4TlU66ylgjKsGF0LasVG2EkZZqx51EooVTC2eWVCLX2nFdL-0006jm7O7sDjF8jZTy7hDG6KfLndRa11pOoPoFryhTKg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2666962116</pqid></control><display><type>article</type><title>The Broken Promise Doctrine: AstraZeneca Canada Inc v Apotex Inc and the Future of Pharmaceutical Patents</title><source>Nexis UK</source><source>CRKN Open Access Journals List</source><creator>Wagner, Darren N</creator><creatorcontrib>Wagner, Darren N</creatorcontrib><description>In AstraZeneca Canada Inc v Apotex Inc, the Supreme Court of Canada abolished the so-called promise doctrine in patent law. Large pharmaceutical companies that sought greater patent protections through litigation routinely mischaracterized the promise doctrine. To demonstrate that mischaracterization, this case comment begins by examining historical and international perspectives that informed the Supreme Court's decision. This paper then turns to a critical yet subjective element of the decision: the analysis of the meaning and purpose of "use" and "useful" in the Patent Act. The reasons for the decision are then considered against the advantages that more stringent utility requirements offer to both patent law and the pharmaceutical industry. This paper concludes with the recent legacy of the decision and recommendations for why and how the courts might seek a middle ground for utility promises in patents.</description><identifier>ISSN: 1205-612X</identifier><language>eng</language><publisher>Appeal Publishing Society</publisher><subject>Litigation ; Patent law ; Pharmaceutical industry ; Supreme Court decisions</subject><ispartof>Appeal, review of current law and law reform, 2022-01 (27), p.70</ispartof><rights>Copyright Appeal Publishing Society 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids></links><search><creatorcontrib>Wagner, Darren N</creatorcontrib><title>The Broken Promise Doctrine: AstraZeneca Canada Inc v Apotex Inc and the Future of Pharmaceutical Patents</title><title>Appeal, review of current law and law reform</title><description>In AstraZeneca Canada Inc v Apotex Inc, the Supreme Court of Canada abolished the so-called promise doctrine in patent law. Large pharmaceutical companies that sought greater patent protections through litigation routinely mischaracterized the promise doctrine. To demonstrate that mischaracterization, this case comment begins by examining historical and international perspectives that informed the Supreme Court's decision. This paper then turns to a critical yet subjective element of the decision: the analysis of the meaning and purpose of "use" and "useful" in the Patent Act. The reasons for the decision are then considered against the advantages that more stringent utility requirements offer to both patent law and the pharmaceutical industry. This paper concludes with the recent legacy of the decision and recommendations for why and how the courts might seek a middle ground for utility promises in patents.</description><subject>Litigation</subject><subject>Patent law</subject><subject>Pharmaceutical industry</subject><subject>Supreme Court decisions</subject><issn>1205-612X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNotzc1KAzEUBeAsFKzVd7jgeiA_nXTG3ThaLRScRQVxUy7JDZ3aJmOSER_fwbo6nMX5zgWbCcnLQgv5fsWuUzpwLiuu5Iz12z3BQwyf5KGL4dQngsdgcuw93UOTcsQP8mQQWvRoEdbewDc0Q8j081fQW8gTshrzGAmCg26P8YSGxtwbPEKHmXxON-zS4THR7X_O2dvqadu-FJvX53XbbIpBCJULTY4TlU66ylgjKsGF0LasVG2EkZZqx51EooVTC2eWVCLX2nFdL-0006jm7O7sDjF8jZTy7hDG6KfLndRa11pOoPoFryhTKg</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Wagner, Darren N</creator><general>Appeal Publishing Society</general><scope/></search><sort><creationdate>20220101</creationdate><title>The Broken Promise Doctrine: AstraZeneca Canada Inc v Apotex Inc and the Future of Pharmaceutical Patents</title><author>Wagner, Darren N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p113t-6ef0ee5f2f8cdc1810116d5839c1c2de9f0f2aee4f34fc7e5a066f0697dee56a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Litigation</topic><topic>Patent law</topic><topic>Pharmaceutical industry</topic><topic>Supreme Court decisions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wagner, Darren N</creatorcontrib><jtitle>Appeal, review of current law and law reform</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wagner, Darren N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Broken Promise Doctrine: AstraZeneca Canada Inc v Apotex Inc and the Future of Pharmaceutical Patents</atitle><jtitle>Appeal, review of current law and law reform</jtitle><date>2022-01-01</date><risdate>2022</risdate><issue>27</issue><spage>70</spage><pages>70-</pages><issn>1205-612X</issn><abstract>In AstraZeneca Canada Inc v Apotex Inc, the Supreme Court of Canada abolished the so-called promise doctrine in patent law. Large pharmaceutical companies that sought greater patent protections through litigation routinely mischaracterized the promise doctrine. To demonstrate that mischaracterization, this case comment begins by examining historical and international perspectives that informed the Supreme Court's decision. This paper then turns to a critical yet subjective element of the decision: the analysis of the meaning and purpose of "use" and "useful" in the Patent Act. The reasons for the decision are then considered against the advantages that more stringent utility requirements offer to both patent law and the pharmaceutical industry. This paper concludes with the recent legacy of the decision and recommendations for why and how the courts might seek a middle ground for utility promises in patents.</abstract><pub>Appeal Publishing Society</pub></addata></record>
fulltext fulltext
identifier ISSN: 1205-612X
ispartof Appeal, review of current law and law reform, 2022-01 (27), p.70
issn 1205-612X
language eng
recordid cdi_proquest_journals_2666962116
source Nexis UK; CRKN Open Access Journals List
subjects Litigation
Patent law
Pharmaceutical industry
Supreme Court decisions
title The Broken Promise Doctrine: AstraZeneca Canada Inc v Apotex Inc and the Future of Pharmaceutical Patents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T20%3A27%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Broken%20Promise%20Doctrine:%20AstraZeneca%20Canada%20Inc%20v%20Apotex%20Inc%20and%20the%20Future%20of%20Pharmaceutical%20Patents&rft.jtitle=Appeal,%20review%20of%20current%20law%20and%20law%20reform&rft.au=Wagner,%20Darren%20N&rft.date=2022-01-01&rft.issue=27&rft.spage=70&rft.pages=70-&rft.issn=1205-612X&rft_id=info:doi/&rft_dat=%3Cproquest%3E2666962116%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p113t-6ef0ee5f2f8cdc1810116d5839c1c2de9f0f2aee4f34fc7e5a066f0697dee56a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2666962116&rft_id=info:pmid/&rfr_iscdi=true